Dss Inc Stock Price, News & Analysis

Document Security Systems, Inc. (DSS) announces an upsized public offering expected to generate approximately $34.5 million in gross proceeds, selling 12,319,346 shares at $2.80 per share. The funds will support the development of new business lines, acquisitions, and working capital. An additional 15% of shares may be purchased by underwriters, potentially raising total proceeds to $39.7 million. The offering is made under a shelf registration effective since May 2019.

Document Security Systems, Inc. (DSS) announced that the record date for its special share dividend of Impact BioMedical has been postponed to a future date, aligned with the S-1 filing for the dividend shares. DSS plans to issue a single special dividend of four Impact BioMedical shares for each DSS share held at the new record date. Despite the intention to take Impact BioMedical public, the statement also highlighted potential uncertainties that could impact this IPO process. Impact BioMedical's technology has been recently valued at up to $933 million, underscoring its significant market potential.

Document Security Systems (DSS) announced the successful exercise of an over-allotment option for its public offering, resulting in an additional 1,000,000 common shares being sold at $3.60 each. This increase brings the total gross proceeds from the offering to approximately $27.6 million. Aegis Capital Corp. acted as the sole bookrunner for this offering, which was registered with the SEC. DSS operates in various sectors including brand protection technology and blockchain security, aiming to enhance shareholder value through strategic business operations.

Aegis Capital Corp. has successfully concluded a $24 million upsized follow-on offering for Document Security Systems (NYSE American: DSS). This move is part of DSS's strategy to enhance its business segments focused on brand protection technology, blockchain security, and healthcare, among others. The company aims to leverage its innovative technologies in counterfeit deterrence and consumer engagement. DSS is led by Chairman Fai Chan, a veteran in corporate restructuring.

Document Security Systems (DSS) has successfully closed an upsized public offering, generating $24 million in gross proceeds. The company issued 6,666,666 shares at a price of $3.60 each, with plans to utilize the funds for developing new business lines, acquisition opportunities, and general corporate needs. Additionally, underwriters have a 45-day option to purchase up to 15% more shares, potentially raising total gross proceeds to approximately $27.6 million.

Document Security Systems, Inc. (DSS) announced an upsized public offering expected to raise approximately $24 million, selling 6,666,666 shares at $3.60 each. Proceeds will support the development of new business lines, acquisitions, and general corporate needs. There is a 45-day option for underwriters to purchase an additional 15% of shares, potentially raising total proceeds to $27.6 million. Aegis Capital Corp. is the sole bookrunner for this offering, which was registered with the SEC on January 19, 2021.

Document Security Systems (DSS) announced that its subsidiary, Impact BioMedical, has entered into an investment and distribution agreement with Nano9 Labs. This partnership aims to enhance DSS's product offerings by adding private-labeled nutraceutical lines to its existing portfolio, leveraging Nano9's advanced delivery technology for better bioavailability. DSS expects this collaboration to boost its direct marketing revenue significantly, especially in the U.S. and Asia. The nutraceutical market is projected to grow substantially, providing ample opportunity for DSS's expansion.

Document Security Systems (DSS) announced that its subsidiary, Impact BioMedical, received a notice of patent allowance for its 3F Biofragrance, a botanical-based insect repellent. The patent protects its method of use against mosquitoes, leveraging terpenes to affect insect receptors. The global insect repellent market is projected to reach $9.6 billion by 2026, indicating significant commercial potential for DSS's innovation. CEO Frank D. Heuszel highlighted the expanded intellectual property estate and the substantial long-term value for shareholders as the product moves toward commercialization.

Document Security Systems (NYSE American: DSS) announced a 10-year exclusive distribution agreement with BioMed Technology Asia Pacific Holdings Limited to market and distribute various probiotic products across key markets including the US, Canada, and South Korea. The company will also purchase shares in BioMed valued at approximately $630,000, allowing them to appoint a director on BioMed’s board. The global probiotics market, valued at $48 billion in 2018, is projected to grow at a CAGR of 6.9% through 2025, indicating potential revenue growth for DSS's subsidiary Impact BioMedical.